Journal
DIABETES
Volume 57, Issue 10, Pages 2666-2671Publisher
AMER DIABETES ASSOC
DOI: 10.2337/db08-0358
Keywords
-
Categories
Funding
- the National Natural Science Foundation of China [30571759]
- the Major Program of PLA of China [04Z007]
- the Major Program of Natural Science Foundation of Fujian Province [2002Y007]
Ask authors/readers for more resources
OBJECTIVE-The aim of this study was to evaluate the efficiency and safety of simultaneous islet and kidney transplantation in patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. RESEARCH DESIGN AND METHODS-Seven patients with type 1 diabetes and end-stage renal failure were transplanted with allogenic islets and kidneys procured from brain-dead donors. To prevent organ rejection, patients received alemtuzumab for induction immunosuppression, followed by sirolimus and tacrolimus. No glucocorticoids were given at any time. RESULTS-The median duration of follow-up was 18.3 months (range 13-31). Kidney survival was 100%. Four patients became insulin independent at 1 year. The other three reduced insulin use to less than 25% of the amount required before transplantation. Serum C-peptide levels were significantly greater posttrans-plant in all patients, indicating continued islet function. No major procedure-related complications were observed. CONCLUSIONS-Our results demonstrate that a steroid-free immunosuppressive regimen consisting of alemtuzumab, sirolimus, and tacrolimus is feasible for simultaneous islet and kidney transplantation. The question of whether this induction regimen is superior to more standard induction deserves large studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available